RXRX RECURSION PHARMACEUTICALS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1601830 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY56.2%
TTM net income YoY33.5%
TTM EPS YoY53.3%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR—
Margins
Gross margin29.2%
Operating margin-725.4%
Net margin-697.1%
FCF margin-458.0%
EBITDA margin-617.2%
Returns
ROE-48.7%
ROA-36.3%
ROIC (approx.)-101.8%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets25.9%
Debt / equity0.01x
Current ratio5.01x
Interest coverage-541.56x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $18.55M | $7.67M | $6.47M | $35.54M | $5.17M | $19.22M | $14.74M | $4.55M |
| Cost of revenue | $10.04M | $11.49M | $12.49M | $14.28M | $14.69M | $20.16M | $21.83M | $12.79M |
| Gross profit | $8.51M | -$3.82M | -$6.02M | $21.26M | -$9.51M | -$938,000 | -$7.08M | -$8.25M |
| R&D expense | $99.12M | $89.61M | $87.90M | $95.94M | $121.06M | $128.64M | $129.63M | $98.33M |
| SG&A expense | $32.56M | $41.53M | $34.59M | $33.66M | $41.63M | $46.65M | $54.65M | $77.19M |
| Operating income | -$123.18M | -$134.97M | -$128.50M | -$108.33M | -$172.20M | -$176.23M | -$191.37M | -$183.77M |
| Interest expense | $266,000 | $309,000 | $350,000 | -$11,000 | $833,000 | $480,000 | $508,000 | $605,000 |
| Pretax income | -$119.01M | -$131.01M | -$122.11M | -$108.10M | -$162.25M | -$171.90M | -$202.65M | -$178.90M |
| Income tax | $25,000 | -$1,000 | -$4.60M | $20,000 | $3,000 | $0 | -$158,000 | $7,000 |
| Net income | -$119.04M | -$131.00M | -$117.50M | -$108.12M | -$162.25M | -$171.90M | -$202.49M | -$178.91M |
| EBITDA | -$106.64M | -$116.80M | -$108.83M | -$88.86M | -$151.16M | -$152.38M | -$172.04M | -$170.82M |
| EPS (basic) | -0.22 | -0.25 | -0.22 | — | -0.36 | -0.41 | -0.50 | — |
| EPS (diluted) | -0.22 | -0.25 | -0.22 | — | -0.36 | -0.41 | -0.50 | — |
| Weighted avg. shares (diluted) | 543.00M | 532.46M | 529.30M | — | 446.99M | 417.36M | 402.77M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $549.85M | $545.68M | $654.47M | $743.29M | $667.14M | $533.85M | $509.16M | $603.02M |
| Current assets | $616.02M | $603.46M | $709.56M | $812.85M | $714.11M | $587.16M | $584.14M | $714.27M |
| PP&E, net | $85.84M | $89.62M | $95.81M | $103.93M | $111.71M | $120.04M | $126.83M | $141.06M |
| Goodwill | $160.71M | $160.35M | $160.17M | $162.16M | $162.04M | $164.27M | $158.11M | $148.87M |
| Intangibles | $273.68M | $282.89M | $294.07M | $309.90M | $322.34M | $341.32M | $335.79M | $335.86M |
| Total assets | $1.22B | $1.21B | $1.34B | $1.47B | $1.40B | $1.30B | $1.31B | $1.45B |
| Current liabilities | $122.92M | $119.89M | $129.70M | $147.71M | $155.10M | $164.03M | $141.98M | $187.47M |
| Short-term debt | $11.81M | $9.44M | $9.27M | $9.09M | $8.92M | $8.75M | $8.59M | $8.43M |
| Long-term debt | $93,000 | $4.75M | $7.18M | $9.56M | $11.90M | $14.20M | $16.45M | $19.02M |
| Total debt | $11.90M | $14.20M | $16.45M | $18.66M | $20.82M | $22.95M | $25.03M | $27.45M |
| Total liabilities | $315.90M | $297.67M | $314.75M | $343.26M | $352.58M | $383.21M | $371.29M | $413.82M |
| Shareholders' equity | $905.81M | $915.00M | $1.02B | $1.13B | $1.05B | $919.15M | $933.95M | $1.03B |
| Net debt | -$537.95M | -$531.49M | -$638.03M | -$724.64M | -$646.32M | -$510.90M | -$484.12M | -$575.58M |
| Shares outstanding | 561.07M | 534.12M | 530.63M | 528.18M | 491.80M | 432.83M | 406.41M | 396.80M |
| Cash flow statement | ||||||||
| Operating cash flow | -$77.41M | -$105.95M | -$81.10M | -$46.07M | -$117.36M | -$76.42M | -$131.96M | -$115.43M |
| Capital expenditure | $407,000 | $44,000 | $258,000 | $1.24M | $243,000 | $3.15M | $1.83M | $1.30M |
| Free cash flow | -$77.81M | -$105.99M | -$81.36M | -$47.32M | -$117.60M | -$79.57M | -$133.79M | -$116.73M |
| Investing cash flow | -$407,000 | -$1.96M | -$338,000 | -$1.24M | -$2.55M | -$5.81M | -$7.27M | $275.46M |
| Financing cash flow | $83.14M | -$1.27M | -$3.47M | $132.01M | $251.34M | $97.66M | $40.53M | $10.64M |
| Depreciation & amortization | $16.54M | $18.17M | $19.67M | $19.48M | $21.04M | $23.85M | $19.33M | $12.95M |
| Stock-based compensation | $23.03M | $19.30M | $22.21M | $23.76M | $25.04M | $25.80M | $36.06M | $30.78M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.